Anna M Roszkowska, R. Spinella, Alessandro Calderone, Marianna Sindoni, Bogumił H. Wowra, Maciej Kozak, Katarzyna Sajak-Hydzik, Jorge Aliò
{"title":"在神经营养性角膜病的治疗中使用 rh-NGF","authors":"Anna M Roszkowska, R. Spinella, Alessandro Calderone, Marianna Sindoni, Bogumił H. Wowra, Maciej Kozak, Katarzyna Sajak-Hydzik, Jorge Aliò","doi":"10.3389/fopht.2024.1408587","DOIUrl":null,"url":null,"abstract":"Neurotrophic keratitis or keratopathy (NK) is a degenerative corneal disease induced by impairment of the trigeminal nerve function. This condition may lead to persistent epithelial defects, corneal ulceration, and perforation. The diagnosis of NK requires a careful investigation of any ocular and systemic condition associated with the disease and ocular surface and corneal sensitivity examinations. In the past, several medical and surgical procedures were used to treat this condition with different clinical effectiveness. Cenegermin is a recombinant human nerve growth factor (rh-NGF) that supports corneal reinnervation. Different clinical trials have demonstrated the safety and efficacy of topical cenegermin in patients with moderate to severe neurotrophic keratitis. In this review, we report the literature on clinical results regarding the treatment of NK with cenegermin since its approval by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) in 2017 and 2018, respectively.","PeriodicalId":73096,"journal":{"name":"Frontiers in ophthalmology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The use of rh-NGF in the management of neurotrophic keratopathy\",\"authors\":\"Anna M Roszkowska, R. Spinella, Alessandro Calderone, Marianna Sindoni, Bogumił H. Wowra, Maciej Kozak, Katarzyna Sajak-Hydzik, Jorge Aliò\",\"doi\":\"10.3389/fopht.2024.1408587\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Neurotrophic keratitis or keratopathy (NK) is a degenerative corneal disease induced by impairment of the trigeminal nerve function. This condition may lead to persistent epithelial defects, corneal ulceration, and perforation. The diagnosis of NK requires a careful investigation of any ocular and systemic condition associated with the disease and ocular surface and corneal sensitivity examinations. In the past, several medical and surgical procedures were used to treat this condition with different clinical effectiveness. Cenegermin is a recombinant human nerve growth factor (rh-NGF) that supports corneal reinnervation. Different clinical trials have demonstrated the safety and efficacy of topical cenegermin in patients with moderate to severe neurotrophic keratitis. In this review, we report the literature on clinical results regarding the treatment of NK with cenegermin since its approval by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) in 2017 and 2018, respectively.\",\"PeriodicalId\":73096,\"journal\":{\"name\":\"Frontiers in ophthalmology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in ophthalmology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3389/fopht.2024.1408587\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fopht.2024.1408587","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
神经营养性角膜炎或角膜病(NK)是一种因三叉神经功能受损而诱发的角膜变性疾病。这种疾病可能导致持续性上皮缺损、角膜溃疡和穿孔。诊断 NK 需要仔细检查与该病相关的任何眼部和全身状况,并进行眼表和角膜敏感性检查。过去,曾有几种药物和手术方法用于治疗这种疾病,但临床效果不一。Cenegermin 是一种重组人神经生长因子(rh-NGF),可支持角膜神经再支配。不同的临床试验已证明,中重度神经营养性角膜炎患者局部使用塞内格尔明具有安全性和有效性。在这篇综述中,我们报告了自欧洲药品管理局(EMA)和美国食品和药物管理局(FDA)分别于 2017 年和 2018 年批准使用 cenegermin 治疗 NK 后的临床结果文献。
The use of rh-NGF in the management of neurotrophic keratopathy
Neurotrophic keratitis or keratopathy (NK) is a degenerative corneal disease induced by impairment of the trigeminal nerve function. This condition may lead to persistent epithelial defects, corneal ulceration, and perforation. The diagnosis of NK requires a careful investigation of any ocular and systemic condition associated with the disease and ocular surface and corneal sensitivity examinations. In the past, several medical and surgical procedures were used to treat this condition with different clinical effectiveness. Cenegermin is a recombinant human nerve growth factor (rh-NGF) that supports corneal reinnervation. Different clinical trials have demonstrated the safety and efficacy of topical cenegermin in patients with moderate to severe neurotrophic keratitis. In this review, we report the literature on clinical results regarding the treatment of NK with cenegermin since its approval by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) in 2017 and 2018, respectively.